Personalized Medicine for Parkinson's Disease New Concepts and Future of Individualized Management

Personalized medicine for Parkinson's disease is a growing and emerging concept in light of recent recognition that Parkinson's is a syndromic condition affecting multiple neurotransmitter systems, as well as brain and extracranial structures. The clinical expression is, thus, heterogeneou...

Full description

Saved in:
Bibliographic Details
Other Authors: Titova, Nataliya (Editor), Chaudhuri, K. Ray (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
Subjects:
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_96636
005 20230202
003 oapen
006 m o d
007 cr|mn|---annan
008 20230202s2023 xx |||||o ||| 0|eng d
020 |a books978-3-0365-6211-7 
020 |a 9783036562124 
020 |a 9783036562117 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-0365-6211-7  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
072 7 |a MJN  |2 bicssc 
100 1 |a Titova, Nataliya  |4 edt 
700 1 |a Chaudhuri, K. Ray  |4 edt 
700 1 |a Titova, Nataliya  |4 oth 
700 1 |a Chaudhuri, K. Ray  |4 oth 
245 1 0 |a Personalized Medicine for Parkinson's Disease  |b New Concepts and Future of Individualized Management 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2023 
300 |a 1 electronic resource (214 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Personalized medicine for Parkinson's disease is a growing and emerging concept in light of recent recognition that Parkinson's is a syndromic condition affecting multiple neurotransmitter systems, as well as brain and extracranial structures. The clinical expression is, thus, heterogeneous, and presentation age can range from the 30s to the 90s, with PD in older patients being associated with significant neuropathological comorbidity as well, involving not just misfolded alpha synuclein deposition but also amyloid and tau. Traditional and largely guideline-driven "one size fits all" management strategies adopted in clinical practice are, therefore, often inadequate in holistic management of a patient, particularly when aspects of motor and nonmotor symptoms are taken into consideration. In this supplement of JPM, we present a selection of papers which address several possible strands of personalized medicine in PD, ranging from genomic precision medicine to digital "checklists" to ensure delivery of holistic personalized medicine involving nonpharmacological strategies, as well. We are soliciting any papers addressing biomarkers, genetics and pharmacogenetics, treatment or complementary therapies for personalized or individualized treatment for PD. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Medicine  |2 bicssc 
650 7 |a Neurology & clinical neurophysiology  |2 bicssc 
653 |a Parkinson's disease 
653 |a movement disorders 
653 |a periodontitis 
653 |a periodontal disease 
653 |a hematologic tests 
653 |a Vitamin D 
653 |a oral health 
653 |a Parkinson's Disease 
653 |a cognition 
653 |a GABAergic signaling 
653 |a cerebellum 
653 |a MRS 
653 |a response inhibition 
653 |a non-motor symptoms 
653 |a carer stress 
653 |a older persons with Parkinson's disease 
653 |a education 
653 |a lifestyle behaviours 
653 |a diet 
653 |a cross-sectional 
653 |a population study 
653 |a neurological disorders 
653 |a precision medicine 
653 |a genetics 
653 |a clinical trials 
653 |a Parkinson's disease (PD) 
653 |a cognitive rehabilitation 
653 |a intervention 
653 |a deep brain stimulation 
653 |a levodopa-carbidopa intestinal gel 
653 |a apomorphine 
653 |a radiofrequency 
653 |a focused ultrasound 
653 |a induced pluripotent stem cells 
653 |a cell therapy 
653 |a gene therapy 
653 |a personalized medicine 
653 |a advanced Parkinson's disease (APD) 
653 |a apomorphine subcutaneous infusion therapy 
653 |a pain 
653 |a intrajejunal 
653 |a levodopa 
653 |a motor and non-motor symptoms 
653 |a PKG (KinetiGrap) 
653 |a rehabilitation 
653 |a device-aided therapies 
653 |a personalised medicine 
653 |a Alzheimer's disease 
653 |a clinical trial 
653 |a impulsive-compulsive disorders (ICD) 
653 |a dopaminergic therapy 
653 |a genetic markers 
653 |a pharmacogenetic 
653 |a polymorphisms 
653 |a insomnia 
653 |a sleep quality 
653 |a assessment 
653 |a young onset Parkinson's (YOPD) 
653 |a Emiratis 
653 |a expatriate 
653 |a genetic 
653 |a epigenetics 
653 |a societal impact 
653 |a device aided therapies 
653 |a quality of life 
653 |a non motor symptoms 
653 |a n/a 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/6581  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/96636  |7 0  |z DOAB: description of the publication